CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Public ClinicalTrials.gov record NCT03454451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.
Study identification
- NCT ID
- NCT03454451
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2018 (Actual)
- Primary completion
- Dec 28, 2022 (Actual)
- Completion
- Feb 19, 2023 (Actual)
- Last update posted
- Dec 21, 2023
2018 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Tucson | Arizona | 85711 | — |
| City Of Hope | Duarte | California | 91010 | — |
| UC San Francisco | San Francisco | California | 94143 | — |
| Yale School of Medicine | New Haven | Connecticut | 06519 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| The John Hopkins University | Baltimore | Maryland | 21224 | — |
| Dana Farber | Boston | Massachusetts | 02215 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| NY Hematology | Albany | New York | 12206 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Carolina BioOncology Institute | Huntsville | North Carolina | 28078 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| University of Oklahoma - Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| UPMC Hillman | Pittsburgh | Pennsylvania | 15232 | — |
| Greenville | Greenville | South Carolina | 29605 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| Virginia Cancer | Fairfax | Virginia | 22031 | — |
| Froedtert Hospital & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03454451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03454451 live on ClinicalTrials.gov.